PMID- 1630544
OWN - NLM
STAT- MEDLINE
DCOM- 19920819
LR  - 20180215
IS  - 1660-8151 (Print)
IS  - 1660-8151 (Linking)
VI  - 61
IP  - 2
DP  - 1992
TI  - Low doses of drugs able to alter intestinal mucosal permeability to food antigens 
      (5-aminosalicylic acid and sodium cromoglycate) do not reduce proteinuria in 
      patients with IgA nephropathy: a preliminary noncontrolled trial.
PG  - 192-5
AB  - In an uncontrolled trial, patients with IgA nephropathy (IgAN) were treated with 
      drugs that can alter the intestinal mucosal permeability to food antigens. These 
      drugs are known to ameliorate urinary abnormalities and histological lesions of 
      IgAN associated with ulcerative colitis or Crohn's disease [5-aminosalicylic acid 
      (5-ASA)] or to prevent, in mice, the induction of IgAN-like disease by oral 
      immunization [disodium cromoglycate (SCG)]. Nine patients [serum creatinine 
      (s-Cr) less than 2 mg/dl; 24-hour proteinuria higher than 1.5 g, but not 
      nephrotic) were treated with 5-ASA (2.4 g/day for 6 months); 9 similar patients 
      were treated with SCG (400 mg/day for 6 months); the follow-up extended to 6 
      months after stopping therapy. The 5-ASA group showed a slight but not 
      significant decrease in s-Cr, 24-hour/proteinuria, IgA circulating immune 
      complexes (IgA-CIC) and IgA rheumatoid factor (IgA-RF); serum beta 
      2-microglobulin and serum IgA were unchanged; 2 of 9 treated patients showed, 
      after 6 months of therapy, a reduction in proteinuria of more than 50% that 
      lasted for the subsequent 18 months. The SCG-treated group showed a slight but 
      not significant increase in 24-hour proteinuria and a significant decrease in 
      serum IgA; unchanged were s-Cr, IgA-CIC, IgA-RF, serum beta 2-microglobulin; no 
      patient treated with SCG showed a reduction in proteinuria of more than 50%. At 
      the dosages and for the periods used, 5-ASA and SCG did not show a significant 
      influence on clinical and laboratory parameters of disease in IgAN; other trials 
      with increased dosages are warranted to definitely ascertain the possible 
      therapeutic role of these drugs in IgAN.
FAU - Bazzi, C
AU  - Bazzi C
AD  - Nephrology and Dialysis Division, San Carlo Borromeo Hospital, Milan, Italy.
FAU - Sinico, R A
AU  - Sinico RA
FAU - Petrini, C
AU  - Petrini C
FAU - Rizza, V
AU  - Rizza V
FAU - Torpia, R
AU  - Torpia R
FAU - Arrigo, G
AU  - Arrigo G
FAU - Ragni, A
AU  - Ragni A
FAU - D'Amico, G
AU  - D'Amico G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Switzerland
TA  - Nephron
JT  - Nephron
JID - 0331777
RN  - 0 (Aminosalicylic Acids)
RN  - 0 (Antigens)
RN  - 4Q81I59GXC (Mesalamine)
RN  - Q2WXR1I0PK (Cromolyn Sodium)
SB  - IM
MH  - Adult
MH  - Aminosalicylic Acids/*pharmacology
MH  - Antigens/metabolism
MH  - Cromolyn Sodium/*pharmacology
MH  - Female
MH  - Food
MH  - Glomerulonephritis, IGA/*drug therapy/urine
MH  - Humans
MH  - Intestinal Mucosa/drug effects/immunology
MH  - Male
MH  - Mesalamine
MH  - Middle Aged
MH  - Permeability/drug effects
MH  - Proteinuria/drug therapy/urine
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1159/000186870 [doi]
PST - ppublish
SO  - Nephron. 1992;61(2):192-5. doi: 10.1159/000186870.